Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive
  • Overview
  • Investor News 2011
  • Investor News 2010
  • Investor News 2009
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2011
  • Ad-hoc 2010
  • Ad-hoc 2009
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2004

Search

Here you find Investor News of year 2004. Ad-hoc messages issued in year 2004 can be found here.

Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR news via E-Mail, RSS Feed or SMS.

Wednesday December 29, 2004

Bayer establishes timetable for stock-market listing:

Lanxess to be placed on the stock market on January 31, 2005

Thursday December 23, 2004

Bayer Evaluating Next Steps for Repinotan Compound

Compound for new type of stroke treatment did not meet the anticipated clinical benefit

Wednesday December 15, 2004

Bayer MaterialScience and Teijin Chemicals sign letter of intent to supply each other with polycarbonate resins

Monday December 13, 2004

Further step to sharpen HealthCare focus

Bayer To Divest its Plasma Products Business To US Investors Cerberus and Ampersand

Kogenate® product line will remain in Bayer’s portfolio

Thursday December 02, 2004

Logical step in Pharma realignment:

Bayer HealthCare adapts pharmaceutical research and development to suit new business conditions

Concentration on therapeutic areas of cancer and cardiovascular risk management including diabetes

Thursday November 25, 2004

Fall Financial News Conference of Bayer AG:

Upward trend at Bayer continues in the third quarter

- Currency- and portfolio-adjusted sales rise by 7 percent / - EBIT before special items triples / - Increased full-year forecasts for sales and underlying EBIT

Monday November 22, 2004

Biological Products Division:

Bayer HealthCare Signs Development Deal for Longer-Acting Kogenate®

Breakthrough liposome technology may allow new treatment paradigm of once weekly dosing in hemophilia A

Friday November 19, 2004

Decision by EU Commission:

Bayer’s acquisition of Roche’s consumer health business approved

Closing expected by turn of the year 2004/2005

Wednesday November 17, 2004

Extraordinary Stockholders’ Meeting of Bayer AG:

Stockholders approve the spin-off of Lanxess

Tuesday November 02, 2004

Bayer and Onyx Announce Results of Phase I Studies Evaluating BAY 43-9006 in Combination with Conventional Chemotherapy Drugs

Friday October 29, 2004

LANXESS received investment grade status

Wednesday October 27, 2004

FDA Grants Orphan Drug Designation to BAY 43-9006 for the Treatment of Renal Cell Carcinoma

Monday October 25, 2004

Bayer HealthCare / Onyx Pharmaceuticals

Bayer and Onyx Announce Positive Phase II Data in Patients with Advanced Kidney Cancer

Companies Confirm Intention to File for Regulatory Approval Based on Ongoing Phase III Study

Friday October 15, 2004

KOGENATE® Bayer with BIO-SET® Approved by European Union Commission, Sets New Standard in Patient Safety and Convenience

Wednesday October 13, 2004

Bayer reaches agreement with U.S. Department of Justice in acrylonitrile-butadiene rubber investigation

Friday October 08, 2004

Package of measures to yield annual savings of EUR 200 million from 2007:

Bayer CropScience confirms profitability targets

Satisfactory operating performance in current year

Wednesday October 06, 2004

Spin-Off Report published:

Bayer sets allotment ratio for Lanxess shares at 10 to 1

- Stockholders to vote on the spin-off on November 17 / - Lanxess issues EUR 200 million mandatory convertible bond to Bayer

Thursday September 30, 2004

Bayer Corporation reaches agreement with U.S. Department of Justice in polyester polyols investigation

Wednesday September 29, 2004

Bayer and Onyx Announce Phase II Results of Treatment with BAY 43-9006 In Patients with Advanced Primary Liver Cancer

52 Percent of Patients Experienced Disease Stabilization or Tumor Shrinkage

Monday September 13, 2004

Further step in the realignment of Bayer HealthCare:

Bayer enters strategic pharmaceuticals alliance with Schering-Plough

- Establishes regional marketing and distribution agreement in the United States and Japan / - Repositions the pharmaceuticals business in the United States / - Creates an Oncology Business Unit with global responsibility

Tuesday August 31, 2004

Bayer’s Interim Report for the Second Quarter of 2004:

EBIT before special items increases by 44 percent

Currency- and portfolio-adjusted sales up 8 percent / Bayer CropScience, Bayer MaterialScience and Lanxess improve significantly / Substantial increase expected in second-half EBIT before special items

Wednesday August 04, 2004

European Commission Grants Orphan Drug Designation to BAY 43-9006 for the Treatment of Renal Cell Carcinoma

Monday July 19, 2004

Bayer to Acquire Roche Consumer Health

Acquisition creates global consumer health care company that will rank among top three worldwide / Acquisition price EUR 2.380 billion including U.S. joint venture

Friday July 16, 2004

Decision by Bayer's Management Board

Lanxess to be spun off to stockholders

Wednesday July 14, 2004

Bayer reaches agreement with U.S. Department of Justice in rubber chemicals investigation

Wednesday July 14, 2004

Bayer sells KWS shares

Company fulfills contractual obligation assumed on acquiring Aventis CropScience

Thursday July 01, 2004

LANXESS starts operating independently

Bayer CEO Wenning: "An important milestone on the road to realigning the Group"

Bayer CEO Wenning: "An important milestone on the road to realigning the Group"

Tuesday June 22, 2004

BAY 59-7939 in tests:

New Bayer drug provides effective and predictable anticoagulation

Study findings announced at the 18th International Congress on Thrombosis

Thursday June 17, 2004

New therapeutic option for the treatment of erectile dysfunction

Levitra® available in Japanese pharmacies from Monday

Levitra® is the first new alternative treatment in five years

Monday June 07, 2004

Encouraging Interim Results on BAY 43-9006 in Advanced Kidney Cancer Presented at American Society of Clinical Oncology (ASCO) Meeting

Data Show Durable Responses in Addition to Tumor Shrinkage and Disease Stabilization

Monday June 07, 2004

Encouraging Data on BAY 43-9006 in Combination with Standard Chemotherapeutics as Melanoma Treatment Presented at American Society of Clinical Oncology Meet

40 Percent of Patients have Durable Partial Responses

Friday June 04, 2004

Bayer CropScience streamlines its management structures

Dr. Rüdiger Scheitza, Dr. Dirk Suwelack and Dr. Wolfgang Welter appointed to the Board of Management

Friday May 28, 2004

Joint news release from BASF, Bayer and Hoechst/Aventis

Platinum Equity signs agreement to acquire DyStar

BASF, Bayer and Hoechst to divest their holdings

Tuesday May 25, 2004

Authorization for Gaucho® in maize suspended in France

Decision of French Agriculture Minister Hervé Gaymard

Wednesday May 19, 2004

FDA approves Avelox® (moxifloxacin HCl) for community acquired pneumonia due to multi-drug resistant Streptococcus PneumoniaE

Approval marks first antibiotic approved to treat resistant strains of most common cause of bacterial pneumonia

Monday May 10, 2004

New data for Levitra™ show fastest ever response time demonstrated of any PDE5 treatment for erectile dysfunction

Separate study shows men think speed of action is more important than long duration when it comes to ED drugs

Monday May 10, 2004

Bayer reports on the first quarter of 2004

Sales and EBIT at high level of the previous year

- EUR 827 million EBIT before special items / - Strong volume growth / - Earnings improved in MaterialScience and Lanxess / - Full-year forecast confirmed

Friday April 30, 2004

Werner Wenning at the Annual Stockholders' Meeting in Cologne:

Bayer: First quarter of 2004 gives grounds for optimism

- Currency- and portfolio-adjusted sales up 9 percent / - EBIT before special items matches the high level of the previous year / - Plan for nearly 60 percent improvement in EBITDA margin by 2006

Thursday April 29, 2004

Levitra awareness and interest expand erectile dysfunction (ED) market

Positive influence of Levitra on Bayer HealthCare's pharmaceuticals business

Global brand management prime example of focused strategy

Wednesday April 28, 2004

Q1 2004 underlying EBIT expected to be about 25-30% above analysts' expectations

- EBIT before special items in Q1 2004 should approximately match last year's high level - Forecast for the full year confirmed

Friday April 23, 2004

Bayer HealthCare Realigns Diagnostics Division as Two Separate Units

Split addresses different market and strategic business needs of Self Testing- and Professional Testing-Systems / Wolfgang Hartwig appointed Global Head of Research and Development in the Pharmaceuticals Division

Monday April 05, 2004

BAY 43-9006 Receives Fast Track Designation from FDA for Metastatic Kidney Cancer Review

Small Molecule Compound in Pivotal Phase III Study

Monday March 22, 2004

Bayer CropScience to purchase Crompton´s share of Gustafson seed treatment business

Acquisition for 124 million US Dollar in North America and Mexico

Thursday March 18, 2004

Werner Wenning at the Spring Financial News Conference on March 18:

Bayer aims to increase EBITDA margin by nearly 60 percent through 2006

2003: EBIT before special items up 67 percent to EUR 1.4 billion / Net loss of EUR 1.4 billion after high special charges / Sales increase by 5 percent before currency translation / Net debt reduced to below EUR 6 billion

Tuesday March 16, 2004

Arthur J. Higgins appointed new head of Bayer HealthCare

Current head Rolf Classon to retire

Thursday March 11, 2004

Bayer proposes €0.50 dividend per share

Operating result improved in 2003 / Balance sheet impacted by impairment charges as announced

Tuesday March 09, 2004

Bayer takes accounting measures in connection with Baycol/Lipobay

Insurers withdraw reservation of rights / EUR 300 million accounting measures for fiscal year 2003

Monday March 08, 2004

Acquisition of Aventis CropScience in 2002

Bayer and Aventis reach agreement on final purchase price

EUR 327 million repayment to Bayer

Thursday February 26, 2004

Study shows Levitra™ (vardenafil HCl) works quickly and provides appropriate window of efficacy, lasting up to 12 hours from time of dosing

Second Study Demonstrates Reliable Efficacy Using Levitra

Wednesday February 04, 2004

Moxifloxacin has Patent Protection in the US until at least 2014

Friday January 16, 2004

Prof. Friedrich Berschauer named new CEO of Bayer CropScience

Dr. Jochen Wulff to retire / Dr. Gunnar Riemann will head up the Animal Health Division of Bayer HealthCare AG